MARTINSRIED, Germany, February 14, 2011 - Scil Technology GmbH, a biopharmaceutical company having its core expertise in protein drug development, formulation and analytics, today announced that Christian Nafe, currently Chief Financial Officer of the company, has been appointed to CEO. He succeeds Dr. Weishui Weiser, who retires after 5 years as Managing Director of Scil Technology.
“I am very happy to take over the role as Scil Technology´s CEO,” said Christian Nafe, „as we are now set for further growth. We have partnered our dental tissue and bone regeneration program with Medtronic, Inc., and in the near future, we aim to close a partnership for CD-RAP, our second lead program, which is in the area of cartilage disorders. In addition, our early-stage pipeline comprises promising projects with blockbuster potential, e.g. in rheumatoid arthritis. We also have been very successful in delivering formulation and analytical services to our partners in the biotechnology and pharmaceutical industry. We therefore will further develop this business through additional collaborations in which Scil Technology will support protein-based drug development.”
Christian Nafe was appointed CFO of Scil Technology in 2003. In parallel, he also served as CFO of other portfolio companies of the Scil Group between 2006 and 2009. From 2002 to 2003, he was interim CEO of Scil Diagnostics GmbH. Prior to joining the Scil Group in April 2000 as Head of Group Controlling, he held positions as Manager of Controlling and later as Head of Controlling at various medium-sized enterprises with international subsidiaries.
“We very much welcome Christian Nafe in his new role and we look forward to participating in Scil Technology´s future progress,” Brian Hunter, Director of BioNet Holding said “We wish to thank Dr. Weishui Weiser for her contributions in making Scil Technology an attractive partner for the biotech and pharma industry.“
About Scil Technology GmbH
Scil Technology is a privately held German biopharmaceutical company developing innovative products through bridging growth factors and biomaterials with particular strengths in recombinant protein know-how, and specific formulation technologies. Scil Technology’s regenerative products are based on various growth factors for bone and cartilage repair. Scil Technology’s long standing development expertise up to clinical Phase III forms a basis to also serve its customers, comprising pharmaceuticals, generics, and medical device companies. Scil Technology GmbH was established in 1999 as an independent company of the Scil Group and is located in the biotechnology cluster Martinsried, Germany, near Munich. Scil Technology GmbH is a wholly owned subsidiary of BioNet Holding GmbH.
For further information please visit: http://www.sciltechnology.com.
Contact:
At Scil Technology:
Iris Margraf
Director of Business Development
t: +49 (0)89 8565 1800
f: +49 (0)89 8565 1818
e:info@sciltechnology.com